Skip to main content
Premium Trial:

Request an Annual Quote

Visual Genomics Releases GenomXoffice, Browser

Premium

COLUMBUS, Ohio--Visual Genomics has announced the launch of its GenomXoffice and BSML Basic Browser for drug discovery and genomics research. Based on Bioinformatics Sequence Markup Language, an open XML standard developed by Visual Genomics and sponsored by the US National Human Genome Research Institute, GenomXoffice provides interactive data visualization to enable researchers to analyze, manage, present, and communicate genomic data from disparate sources.

GenomXoffice's integrated suite of bioinformatics components includes BSML Browser Plus, Librarian, Sequence Editor, BSML Document Editor, GenomXtools, and Query Manager.

The other new release, BSML Basic Browser, can be downloaded for free from Visual Genomics' web site (http://www.visualgenomics.com). Basic Browser displays BSML documents and imports gene sequences from local or remote repositories such as GenBank. These are the first commercial software releases for the two-year-old self-funded company, which has several hundred, mostly academic, customers using an older version of the software.

Filed under

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.